Novo Nordisk's High-Dose Wegovy Approved

Novo Nordisk A/S has secured U.S. approval for a higher-dose formulation of its successful Wegovy obesity medication. This regulatory green light allows the company to offer a treatment option that provides weight loss results more comparable to rival Eli Lilly's Zepbound. The approval is a significant boost for Novo Nordisk, strengthening its position in the competitive and rapidly growing weight-loss drug market. This expansion of its product offering is expected to drive further sales and market share gains for the pharmaceutical giant.